Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1953 1
1954 1
1955 5
1956 4
1957 11
1958 5
1959 3
1960 4
1961 4
1962 12
1963 9
1964 9
1965 18
1966 14
1967 13
1968 18
1969 12
1970 12
1971 11
1972 10
1973 17
1974 5
1975 27
1976 12
1977 15
1978 23
1979 23
1980 16
1981 23
1982 23
1983 46
1984 50
1985 39
1986 68
1987 60
1988 58
1989 85
1990 81
1991 83
1992 61
1993 74
1994 61
1995 63
1996 76
1997 74
1998 88
1999 88
2000 82
2001 66
2002 94
2003 81
2004 116
2005 126
2006 172
2007 174
2008 181
2009 194
2010 186
2011 214
2012 204
2013 206
2014 253
2015 279
2016 274
2017 245
2018 210
2019 230
2020 282
2021 320
2022 264
2023 253
2024 91

Text availability

Article attribute

Article type

Publication date

Search Results

5,738 results

Results by year

Filters applied: . Clear all
Page 1
Essential Thrombocythemia.
Tefferi A, Pardanani A. Tefferi A, et al. N Engl J Med. 2019 Nov 28;381(22):2135-2144. doi: 10.1056/NEJMcp1816082. N Engl J Med. 2019. PMID: 31774958 Review. No abstract available.
Essential thrombocythemia: challenges in clinical practice and future prospects.
Godfrey AL, Green AC, Harrison CN. Godfrey AL, et al. Blood. 2023 Apr 20;141(16):1943-1953. doi: 10.1182/blood.2022017625. Blood. 2023. PMID: 36379024 Review.
Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding the molecular pathogenesis and which patients may have greatest risk of progression or vascular events. ...
Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding t
A review of essential thrombocythemia and its complications.
Babakhanlou R, Masarova L, Verstovsek S. Babakhanlou R, et al. Clin Adv Hematol Oncol. 2023 Feb;21(2):76-84. Clin Adv Hematol Oncol. 2023. PMID: 36780473 Review.
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by an increased platelet count in the peripheral blood and excessive megakaryopoiesis in the bone marrow. ...
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by an increased platelet count in the pe
Current management strategies for polycythemia vera and essential thrombocythemia.
Guglielmelli P, Vannucchi AM. Guglielmelli P, et al. Blood Rev. 2020 Jul;42:100714. doi: 10.1016/j.blre.2020.100714. Epub 2020 Jun 3. Blood Rev. 2020. PMID: 32546373 Review.
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiovascular events, a varying burden of symptoms, and an intrinsic risk of evolution to secondary forms of myelofibrosis and acute leukem …
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of …
Essential thrombocythemia.
Harrison CN, Green AR. Harrison CN, et al. Hematol Oncol Clin North Am. 2003 Oct;17(5):1175-90, vii. doi: 10.1016/s0889-8588(03)00082-0. Hematol Oncol Clin North Am. 2003. PMID: 14560781 Review.
Essential thrombocythemia is a distinct clinical entity within the spectrum of myeloproliferative disorders. There is as yet no pathognomonic diagnostic test, and patients who currently fall into the category of essential thrombocythemia are likely to
Essential thrombocythemia is a distinct clinical entity within the spectrum of myeloproliferative disorders. There is as yet n
Essential thrombocythemia.
Finazzi G, Harrison C. Finazzi G, et al. Semin Hematol. 2005 Oct;42(4):230-8. doi: 10.1053/j.seminhematol.2005.05.022. Semin Hematol. 2005. PMID: 16210036 Review.
Significant progress in our understanding of the molecular pathogenesis of essential thrombocythemia (ET) and the other Philadelphia (Ph) chromosome-negative myeloproliferative disorders (MPDs) has recently been achieved. ...
Significant progress in our understanding of the molecular pathogenesis of essential thrombocythemia (ET) and the other Philad …
Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.
Iurlo A, Bucelli C, Cattaneo D. Iurlo A, et al. Curr Treat Options Oncol. 2023 Jul;24(7):802-820. doi: 10.1007/s11864-023-01099-8. Epub 2023 May 17. Curr Treat Options Oncol. 2023. PMID: 37195587 Review.
Current treatment of essential thrombocythemia (ET) should primarily prevent thrombo-hemorrhagic events, without increasing the rate of fibrotic progression or leukemic evolution, and secondarily control microvascular symptoms. ...
Current treatment of essential thrombocythemia (ET) should primarily prevent thrombo-hemorrhagic events, without increasing th …
Essential thrombocythemia.
Schafer AI. Schafer AI. Prog Hemost Thromb. 1991;10:69-96. Prog Hemost Thromb. 1991. PMID: 2008534 Review. No abstract available.
Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.
Puglianini OC, Peker D, Zhang L, Papadantonakis N. Puglianini OC, et al. Lab Med. 2023 Jan 5;54(1):13-22. doi: 10.1093/labmed/lmac074. Lab Med. 2023. PMID: 35960786 Review.
In this review, we discuss the mutational landscape of patients with essential thrombocythemia (ET), prognostic scores and salient pathology, and clinical points. We discuss also the diagnostic challenges of differentiating ET from prefibrotic MF. We then focus on p …
In this review, we discuss the mutational landscape of patients with essential thrombocythemia (ET), prognostic scores and sal …
Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis.
Maleknia M, Shahrabi S, Ghanavat M, Vosoughi T, Saki N. Maleknia M, et al. Mol Biol Rep. 2020 Jun;47(6):4767-4778. doi: 10.1007/s11033-020-05536-x. Epub 2020 May 30. Mol Biol Rep. 2020. PMID: 32472297 Review.
Essential thrombocythemia (ET) is a classical myeloproliferative neoplasm that is susceptible to hypercoagulable state due to impaired hemostatic system, so that thrombotic complications are the leading cause of mortality in ET patients. The content used in this art
Essential thrombocythemia (ET) is a classical myeloproliferative neoplasm that is susceptible to hypercoagulable state due to
5,738 results